Controversies in the adjuvant treatment of breast cancer: New adjuvant endocrine treatment strategies

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  D'Hondt, V ^a   Piccart, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CELECOXIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; LETROZOLE; METHOTREXATE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FATIGUE; FRACTURE; GYNECOLOGIC DISEASE; HEADACHE; HOT FLUSH; HUMAN; LONG TERM CARE; LUNG CANCER; MELANOMA; META ANALYSIS; METASTASIS; MOOD DISORDER; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; SHORT COURSE THERAPY; THROMBOEMBOLISM; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PATIENT SELECTION; POSTMENOPAUSE;

EID: 9744232130     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh901     Document Type: Article

References (27)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
2. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
3. Bonneterre J, Thurlimann B, Robertson JFR et al. Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757.
4. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast carcinoma in postmenopauxsal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18: 3758-3767.
5. Paridaens R, Therasse P, Dirix L et al. First results of a randomized phase III trial comparing exemestane, versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC)-EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group. Eur J Cancer 2004; 2 (Suppl): 126(Abstr 241).
6. ATAC Trialists' Group. Anastrozole, alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
7. Dowsett M, on behalf of the ATAC Trialists Group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003; 82 (Suppl 1): S7(Abstr 4).
8. Baum M, Budzar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1779-1781.
9. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. J Clin Oncol 2002; 20: 3317-3327.
10. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003; 21: 2597-2599.
11. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
12. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of Tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-690.
13. Stewart HJ, Prescott RJ, Forrest PM. Scottisch adjuvant Tamoxifen trial: a randomised study updated to 15 years. J Natl Cancer Inst 2001; 93: 456-462.
14. Tormey DC, Gray R, Falkson HC. Post-chemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node positive breast cancer. J Natl Cancer Inst 1996; 88: 1828-1833.
15. Goss P, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
16. Boccardo F, Rubagotti A, Amoroso D et al. on behalf of the Italian Tamoxifen Arimidex (ITA) trial. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifien treatment. Breast Cancer Res Treat 2003; 82 (Suppl 1): S6(Abstr 3).
17. Coombes RC, Hall E, Gibson LJ et al. for the Intergroup Exemestane Study (IES). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
18. Piccart MJ. New stars in the sky of treatment for early breast cancer. N Engl J Med 2004; 350: 1140-1142.
19. Dixon JM. Neoadjuvant endocrine therapy. In Miller WR, Santen RJ (eds): Aromatase Inhibition and Breast Cancer. New York: Marcel Dekker 2000; 103-116.
20. Dixon JM, Love CDB, Bellamy COC et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001; 66: 191-199.
21. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002; 9 (Suppl): 9-15.
22. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527-1532.
23. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1 and/or Erb2 positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
24. Smith I, Dowsett M, on behalf of the IMPACT ttialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 2003; 82 (Suppl 1): S6(Abstr 1).
25. Dowsett M, Smith I, on behalf of the IMPACT trialists. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than with tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: a potential predictor of relapse-free survival. Breast Cancer Res Treat 2003; 82 (Suppl 1): S6(Abstr 2).
26. Pritchard KI. The best use of adjuvant endocrine treatments. Breast 2003; 12: 497-508.
27. Piccart MJ, Goldhirsch A, on behalf of the Breast International Group. An over-view of recent and ongoing clinical trials for breast cancer. Straehle C (ed.): Breast International Group London, Greenwich Medical Media Ltd, 2003, 3rd edition.